- Photocure ASA: Results for the first quarter of 2024
- Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
- Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
- Photocure ASA - Notice of the Annual General Meeting 23 May 2024
- Photocure ASA: Annual Report 2023
- European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care
- Photocure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
- Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
More ▼
Key statistics
As of last trade Photocure ASA (PHO:OSL) traded at 57.90, -19.47% below its 52-week high of 71.90, set on Jan 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.40 |
---|---|
High | 59.40 |
Low | 57.50 |
Bid | 57.90 |
Offer | 58.00 |
Previous close | 59.20 |
Average volume | 113.43k |
---|---|
Shares outstanding | 27.12m |
Free float | 26.68m |
P/E (TTM) | 388.72 |
Market cap | 1.57bn NOK |
EPS (TTM) | 0.149 NOK |
Data delayed at least 15 minutes, as of May 22 2024.
More ▼